title: [Value of cardiac troponin I measurement in prediction of anthracycline-induced cardiotoxicity in breast cancer patients].
abstract: OBJECTIVE
  To evaluate the value of cardiac troponin I (CTnI) measurement in predicting anthracycline-induced cardiotoxicity in patients with breast cancer.
  
  
  METHODS
  This study was conducted among 186 breast cancer patients receiving anthracycline-based chemotherapy. Serum cTnI concentrations before and after each cycle of the chemotherapy and the left ventricular ejection fraction (LVEF) before and at the 2nd, 4th and 6th months of the treatment were recorded. According to serum cTnI concentration, the patients were divided into CTnI+ group (with serum CTnI concentration of no less than 0.1 ng/ml, n=60) and CTnI- (<0.1 ng/ml) group (n=126).
  
  
  RESULTS
  No patients in this series experienced cardiac heart failure (CHF). The number of patients with a LVEF reduction by over 10% from the baseline was 16 (26.7%) in CTnI+ group, as compared to 7 (5.6%) in CTnI- group, showing a significant difference between the two groups (P<0.01).
  
  
  CONCLUSIONS
  CTnI can be a useful marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer.
authors.affiliation: Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. doctor.hwb@163.com
authors.forename: Wei-bin
authors.initials: WB
authors.lastname: Huang
authors.forename: Guang-yu
authors.initials: GY
authors.lastname: Yao
authors.forename: Min-feng
authors.initials: MF
authors.lastname: Liu
authors.forename: Rui-ting
authors.initials: RT
authors.lastname: Chen
authors.forename: Lu-jia
authors.initials: LJ
authors.lastname: Chen
authors.forename: Jian-yu
authors.initials: JY
authors.lastname: Dong
authors.forename: Fan
authors.initials: F
authors.lastname: Gu
authors.forename: Zhao-ze
authors.initials: ZZ
authors.lastname: Guo
authors.forename: Chang-sheng
authors.initials: CS
authors.lastname: Ye
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy*; D054715:Cardiotoxins / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D019210:Troponin I / Q000097:blood*; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D054715:Cardiotoxins; D019210:Troponin I